Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that tadalafil use was associated with a decreased risk of major adverse cardiac events and venous thromboembolism in men with lower urinary tract symptoms.

This study found that patients with alopecia areata had a higher incidence rate of herpes simplex infection compared to matched individuals without the condition.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.

This review discusses the diagnosis, management, and hormone treatment of transsexual individuals, and examines the risks and effects of cross-sex hormone therapy without presenting new clinical results.

This review discusses the physiological skin changes during pregnancy and reports no new clinical results, emphasizing the importance of distinguishing these changes from pathological conditions.

This article discusses the causes, prevention, and management of complications following face-lift surgery but reports no new clinical results.

This article discusses various hormonal therapies for acne and provides practical treatment guidelines for managing hormonally related acne, but it reports no new research findings.

This report discusses two cases of kidney transplantation in transgender patients and highlights the complexities of managing gender-affirming care alongside post-transplantation health, including hormone therapy and associated risks.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This article states that hormone therapy with estrogens and antiandrogens for transgender females is within an obstetrician-gynecologist's practice scope and involves careful dosing and monitoring to manage short-term thrombotic risks.

This literature review of hormonal implants in Brazil highlights their expanding usage beyond contraceptive and hormone replacement purposes, noting aesthetic desires like muscle mass gain. However, significant side effects such as cardiovascular events and psychological complications are frequently reported, potentially outweighing the benefits.

This article reviews androgen excess and cardiometabolic risks in women, highlighting increased cardiovascular disease risk in those with polycystic ovary syndrome, but reports no new clinical results.

A woman had a delayed allergic reaction to the blood thinner enoxaparin, treated with a steroid cream.

In this article, the authors reviewed essential terminology and recommendations for creating a welcoming healthcare environment for transgender patients and providing gender-affirming therapy, emphasizing the unique health needs and disparities faced by this population.

In this study, older women aged 70 and above, treated for sexual dysfunction using carefully monitored hormone therapy, reported improvements in sexual function and symptom relief, with no incidences of cancer or thromboembolic events, though some experienced breast tenderness and hair changes.

This case report details a probable severe adverse event associated with ritlecitinib for alopecia areata, highlighting risks of pulmonary emboli, infection, atrial fibrillation, and acute kidney injury despite an absence of known risk factors.

This study found that patients with rheumatoid arthritis taking tofacitinib had higher rates of serious adverse events compared to those with alopecia areata, highlighting the need for careful assessment when using it off-label for alopecia areata.

This research highlights that while JAK inhibitors are effective for various inflammatory conditions, studies raise concerns about increased risks of venous and arterial thromboembolism, and cancer, particularly with tofacitinib and baricitinib, leading to European guidelines recommending caution in high-risk patients.

This review highlights that long-term health consequences of COVID-19, affecting multiple body systems, persist after acute infection, necessitating a comprehensive management approach that includes interdisciplinary care and lifestyle interventions to mitigate long-term damage.

This study found that oral estradiol was generally effective in achieving target 17-β estradiol levels in transgender women, but often failed to suppress testosterone adequately, with variability in individual responses.

This review explores current and emerging treatments for polycystic ovary syndrome, focusing on managing hyperandrogenism and cardiometabolic risk, but reports no new clinical results.

This review discusses sex and gender differences in COVID-19 presentation, treatment, and outcomes, and reports no new clinical findings.

This review discusses sex differences in immune response to respiratory viral infections, including SARS-CoV-2, and highlights that hormones like estrogen may provide females with better protection, but it reports no new results.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

The moisturizing cream used after a chemical peel was well tolerated and effectively moisturized the skin.

Patients with multiple superficial venous thrombosis are at greater risk for serious complications like cancer and recurrent blood clots.

This review discusses the 2011 publications on the side effects of sex hormones and related compounds, without reporting new clinical results.

This review examines the gender-specific challenges in preventing and treating venous thromboembolism in women and highlights the need for further research on safe and optimal treatment strategies.

This study examined data from the FDA Adverse Event Reporting System and found that finasteride use is linked with both known and previously unlisted adverse events, such as erectile dysfunction and post-5α reductase inhibitor syndrome, with variations observed by age and sex.